dopamine agonists

Summary

Summary: Drugs that bind to and activate dopamine receptors.

Top Publications

  1. pmc Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration
    Roshan Cools
    Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    J Neurosci 29:1538-43. 2009
  2. pmc Dopamine agonists and risk: impulse control disorders in Parkinson's disease
    Valerie Voon
    Behavioural and Clinical Neurosciences Institute, Department of Experimental Psychology, Downing Site, University of Cambridge, Cambridge CB2 3EB, UK
    Brain 134:1438-46. 2011
  3. ncbi A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol
    Michael J Frank
    Department of Psychology and Program in NeuroscienceUniversity of Arizona, Tucson, AZ 85721, USA
    Behav Neurosci 120:497-517. 2006
  4. ncbi The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
    P Sokoloff
    INSERM, Unité de Neurobiologie et Pharmacologie, Moléculaire U573, Centre Paul Broca, 2ter rue d Alesia, 75014 Paris, France
    CNS Neurol Disord Drug Targets 5:25-43. 2006
  5. pmc Association of dopamine agonist use with impulse control disorders in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and Parkinson s Disease Research, Education, and Clinical Center, USA
    Arch Neurol 63:969-73. 2006
  6. pmc Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients
    Nikoletta Bodi
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Brain 132:2385-95. 2009
  7. ncbi Advances in the treatment of prolactinomas
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Endocr Rev 27:485-534. 2006
  8. ncbi A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Lancet Neurol 8:929-37. 2009
  9. ncbi Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome
    Andrew H Evans
    Reta Lila Weston Institute of Neurological Studies, London, United Kingdom
    Mov Disord 19:397-405. 2004
  10. doi In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice
    Eugenii A Rabiner
    GlaxoSmithKline Clinical Imaging Centre, Hammersmith Hospital, London, UK
    Synapse 63:782-93. 2009

Detail Information

Publications305 found, 100 shown here

  1. pmc Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration
    Roshan Cools
    Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    J Neurosci 29:1538-43. 2009
    ..These data demonstrate that the effects of D(2) receptor stimulation on reversal learning in humans depend on task demands and baseline striatal dopamine synthesis capacity...
  2. pmc Dopamine agonists and risk: impulse control disorders in Parkinson's disease
    Valerie Voon
    Behavioural and Clinical Neurosciences Institute, Department of Experimental Psychology, Downing Site, University of Cambridge, Cambridge CB2 3EB, UK
    Brain 134:1438-46. 2011
    ..taking task while performing functional magnetic resonance imaging, we investigated the relationship between dopamine agonists and risk taking in patients with Parkinson's disease with and without impulse control disorders...
  3. ncbi A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol
    Michael J Frank
    Department of Psychology and Program in NeuroscienceUniversity of Arizona, Tucson, AZ 85721, USA
    Behav Neurosci 120:497-517. 2006
    ..Drug effects interacted with baseline working memory span in all tasks. Taken together, the results support a unified account of the role of dopamine in modulating cognitive processes that depend on the basal ganglia...
  4. ncbi The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
    P Sokoloff
    INSERM, Unité de Neurobiologie et Pharmacologie, Moléculaire U573, Centre Paul Broca, 2ter rue d Alesia, 75014 Paris, France
    CNS Neurol Disord Drug Targets 5:25-43. 2006
    ..These data allow us to propose novel treatment options in PD, schizophrenia and drug addiction, which are awaiting evaluation in clinical trials...
  5. pmc Association of dopamine agonist use with impulse control disorders in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and Parkinson s Disease Research, Education, and Clinical Center, USA
    Arch Neurol 63:969-73. 2006
    ..To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD)...
  6. pmc Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients
    Nikoletta Bodi
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Brain 132:2385-95. 2009
    ..The never-medicated patients were also re-evaluated after 12 weeks of treatment with dopamine agonists. Reward and punishment processing was assessed by a feedback-based probabilistic classification task...
  7. ncbi Advances in the treatment of prolactinomas
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Endocr Rev 27:485-534. 2006
    ..Medical therapy with dopamine agonists is highly effective in the majority of cases and represents the mainstay of therapy...
  8. ncbi A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Lancet Neurol 8:929-37. 2009
    ..Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa...
  9. ncbi Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome
    Andrew H Evans
    Reta Lila Weston Institute of Neurological Studies, London, United Kingdom
    Mov Disord 19:397-405. 2004
    ..We believe that this is an underreported, socially disabling phenomenon that is commonly associated with the syndrome of dopamine dysregulation and is phenomenologically distinct from both obsessive-compulsive disorder and mania...
  10. doi In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice
    Eugenii A Rabiner
    GlaxoSmithKline Clinical Imaging Centre, Hammersmith Hospital, London, UK
    Synapse 63:782-93. 2009
    ..The midbrain is thus an excellent target region to examine D3 receptor occupancy with [(11)C]-(+)-PHNO PET in vivo...
  11. doi Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis
    Evelien D M Rooke
    Department of Clinical Neurosciences, Centre for Clinical Brain Sciences, University of Edinburgh, Royal Infirmary of Edinburgh, UK
    Parkinsonism Relat Disord 17:313-20. 2011
    ..In this study we use these tools to describe the reported efficacy of dopamine agonists in animal models of PD.
  12. ncbi Dopamine modulates excitability of spiny neurons in the avian basal ganglia
    Long Ding
    Department of Zoology, University of Washington, Seattle, Washington 98195 6115, USA
    J Neurosci 22:5210-8. 2002
    ..The diversity of DA actions enables the DA system to fine-tune the dynamics of the song system and allows flexible control over song learning and production...
  13. ncbi Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature
    Stephane Thobois
    Hopital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France
    Clin Ther 28:1-12. 2006
    ..However, the equivalence of doses of dopamine receptor agonists before and after switching drugs remains empirical because few clinical trials have addressed this issue...
  14. doi Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925
    Ariel Graff-Guerrero
    PET Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Int J Neuropsychopharmacol 13:273-87. 2010
    ..Thus, [11C](+)-PHNO seems a suitable PET radiotracer to estimate D3 receptor occupancy in humans...
  15. doi Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis
    William L Baker
    School of Pharmacy, University of Connecticut, CT, USA
    Parkinsonism Relat Disord 15:287-94. 2009
    Our objective was to perform a meta-analysis of randomized controlled trials of dopamine agonists (DA) as monotherapy as well as adjunctive therapy for the early treatment of Parkinson's disease (PD)...
  16. ncbi Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation
    Stacy A Castner
    Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Neurosci 24:1446-50. 2004
    ....
  17. pmc The risky business of dopamine agonists in Parkinson disease and impulse control disorders
    Daniel O Claassen
    Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
    Behav Neurosci 125:492-500. 2011
    ..disease (PD), impulse control disorder (ICD) can result from dopaminergic medication use, particularly dopamine agonists (DAA)...
  18. ncbi Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade
    Takeshi Kihara
    Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Neurosci Res 70:274-82. 2002
    ....
  19. doi Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis
    Mohamed A F M Youssef
    Department of Obstetrics and Gynaecology, Cairo University, Cairo, Egypt
    Hum Reprod Update 16:459-66. 2010
    Recently, dopamine agonists were proposed as a prophylactic treatment for ovarian hyperstimulation syndrome (OHSS) in women at high risk in IVF/ICSI treatment cycles.
  20. ncbi Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease
    Francesca Romana Pezzella
    Department of Neurological Sciences, La Sapienza University, Rome, Italy
    Mov Disord 20:77-81. 2005
    ..study showed a significant correlation between HHD and a previous history of mood disorders, and the use of dopamine agonists, either in monotherapy or in combination...
  21. pmc Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD
    T van Eimeren
    Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Canada
    Neurology 75:1711-6. 2010
    Some patients with Parkinson disease (PD) develop pathological gambling when treated with dopamine agonists (DAs)...
  22. doi Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management
    Sean S O'Sullivan
    Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, London, England
    CNS Drugs 23:157-70. 2009
    ..considered the most potent trigger for DDS in Parkinson's disease, but subcutaneous apomorphine and oral dopamine agonists may also be responsible...
  23. ncbi Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation
    H Y Wang
    Department of Pharmacology, Medical College of Pennsylvania, Philadelphia 19129, USA
    Mol Pharmacol 48:988-94. 1995
    ..The data provide evidence to suggest that in addition to coupling to Gs/adenylyl cyclase, D1-like dopamine sites that couple to Gq may mediate dopamine-stimulated formation of inositol phosphates in the rat striatum...
  24. pmc Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task
    Marie Astrid Pezze
    Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Neuropsychopharmacology 32:273-83. 2007
    ..The data are discussed in terms of the different functions of NAC dopamine receptors in the processing of information from its different cortico-limbic inputs...
  25. ncbi Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists
    Steven P Presgraves
    Molecular and Cellular Biology Graduate Group, Arizona State University, Tempe, AZ, USA
    Neurotox Res 5:579-98. 2004
    ..Further characterization of the neuroprotective effects of DA agonists in this model system can provide unique information about DA receptor dependent and independent mechanisms of neuroprotection...
  26. ncbi Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms
    Kuei Y Tseng
    Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York 12208, USA
    J Neurosci 24:5131-9. 2004
    ..Thus, the modulatory actions of D1 and D2 receptors on PFC pyramidal cell excitability are mediated by multiple intracellular mechanisms and by activation of GABA(A) receptors, depending on the glutamate receptor subtypes involved...
  27. ncbi Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis
    Olaf M Dekkers
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Endocrinol Metab 95:43-51. 2010
    b>Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprolactinemia. However, the optimal treatment strategy and treatment duration is not clear in all details.
  28. doi Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
    J Kreutzer
    Department of Neurosurgery, University of Erlangen Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Eur J Endocrinol 158:11-8. 2008
    Medical therapy with dopamine agonists (DA) is the primary treatment of choice in most patients with prolactinomas. 'Classical' surgical indications are intolerance or lack of efficiency of DA therapy...
  29. ncbi A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 90:4405-10. 2005
    ....
  30. ncbi The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery
    Rosario Pivonello
    Department of Molecular and Clinical, Endocrinology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:223-30. 2009
    The role of dopamine agonists in the treatment of Cushing's disease (CD) has been previously debated.
  31. ncbi Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial
    Werner H Poewe
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Lancet Neurol 6:513-20. 2007
    ....
  32. pmc Dopamine modulation of GABA tonic conductance in striatal output neurons
    Megan J Janssen
    Department of Physiology and Biophysics, Georgetown University School of Medicine, Washington, DC 20007, USA
    J Neurosci 29:5116-26. 2009
    ..Our results suggest that distinct phosphorylation of beta3-subunits may cause larger tonic current in D2+ striatopallidal MSNs, and proper intracellular conditions can reveal tonic current in D1+ cells...
  33. pmc Dopamine agonist increases risk taking but blunts reward-related brain activity
    Jordi Riba
    Department of Neuropsychology, University of Magdeburg, Magdeburg, Germany
    PLoS ONE 3:e2479. 2008
    ....
  34. pmc Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors
    Julie A Przybyla
    Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA
    Eur Neuropsychopharmacol 19:138-46. 2009
    ..These findings demonstrate a reversed stereoselectivity for the enantiomers of DOX at D(1) and alpha(2C) receptors and have implications for the therapeutic utility of doxanthrine...
  35. pmc Burning mouth syndrome responsive to pramipexol
    J Stuginski-Barbosa
    The Department of Neurology, School of Medicine at Ribeirao Preto, Ribeirao Preto, SP, Brazil
    J Headache Pain 9:43-5. 2008
    ..We discuss potential pathophysiological implications of our findings...
  36. doi Three cases of delusional parasitosis caused by dopamine agonists
    S Flann
    Department of Dermatology, Orpington Hospital, Orpington, Kent, UK
    Clin Exp Dermatol 35:740-2. 2010
    We report three cases of delusional parasitosis (DP) in patients with well-established Parkinson's disease, all of whom were taking dopamine agonists. In all three cases, the DP resolved rapidly when the drug was withdrawn.
  37. doi Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom
    Virginie Czernecki
    Center d Investigation Clinique, Federation de Neurologie, INSERM Unit 679, Paris, France
    Mov Disord 23:964-9. 2008
    ....
  38. doi Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage
    Ju Hee Lim
    College of Pharmacy and Research Institute of Drug Development, Chonnam National University, 300 Yongbong Dong, Buk Gu, Gwangju 500 757, South Korea
    Pharmacol Res 57:325-31. 2008
    ..Taken together, we investigate the novel cytoprotective effect of bromocriptine involving PI3K- and Nrf2-mediated upregulation of the antioxidant enzyme NQO1...
  39. ncbi Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials
    Jaime Kulisevsky
    Unit of Movement Disorders, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Drug Saf 33:147-61. 2010
    b>Dopamine agonists have a well established role in the treatment of Parkinson's disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.
  40. ncbi Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease
    Dirk Deleu
    College of Medicine, Sultan Qaboos University, PO Box 35, Al Khod, Sultanate of Oman
    Clin Pharmacokinet 41:261-309. 2002
    ..Drugs for which there is at least some evidence for neuroprotective effect are certain dopamine agonists, amantadine and MAO-B inhibitors (selegiline)...
  41. pmc Investigation of D₂ receptor-agonist interactions using a combination of pharmacophore and receptor homology modeling
    Marcus Malo
    Department of Chemistry, Medicinal Chemistry, University of Gothenburg, 41296 Goteborg, Sweden
    ChemMedChem 7:471-82, 338. 2012
    ..The strategy has the potential to identify weaknesses in the individual models and thereby provides an opportunity to improve the discriminating predictivity of both pharmacophore searches and structure-based virtual screens...
  42. ncbi Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease
    John D McCorvy
    Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy and Integrative Neuroscience Program, Purdue University, West Lafayette, IN 47907, USA
    Psychopharmacology (Berl) 222:81-7. 2012
    ..Recently, we discovered doxanthrine (DOX), an oxygen bioisostere of DHX that has even greater selectivity for the D₁ dopamine receptor...
  43. ncbi Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease
    Robert B McCall
    Pfizer, Inc, Kalamazoo, MI 49007, USA
    J Pharmacol Exp Ther 314:1248-56. 2005
    ..In summary, sumanirole is the first published selective D(2) receptor agonist. The compound has activity in animal models of dopamine hypofunction and has a high level of efficacy in animal models of Parkinson's disease...
  44. ncbi A novel dopamine agonist for the transdermal treatment of Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, United Kingdom
    Neurology 65:S3-5. 2005
    ..The pharmacologic properties of rotigotine suggest that it has the characteristics necessary to form the basis of a transdermal treatment for the control of motor symptoms of PD...
  45. ncbi Tremor and dopamine agonists
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL 62794 9643, USA
    Neurology 58:S57-62. 2002
    ..Comparable improvement is achieved with the dopamine agonists. Dopamine agonists are particularly well suited for patients with newly diagnosed tremor-predominant disease ..
  46. ncbi Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain
    Gráinne C O'Keeffe
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Cell Cycle 8:2888-94. 2009
    ..This result has implications for the use of dopaminergic therapies in PD and in the development of such therapies focusing on upregulating SVZ neurogenesis...
  47. pmc Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
    Muriel Babey
    Department of Neurosurgery, University of Berne, Inselspital, 3010, Berne, Switzerland
    Pituitary 14:222-30. 2011
    ..5 months. Patients with small prolactinomas can safely consider pituitary surgery in a specialized centre with good chance of long-term remission as an alternative to long-term DA therapy...
  48. ncbi Practical considerations in the use of apomorphine injectable
    Annette Bowron
    Jubilee Day Hospital, North Tyneside General Hospital, Tyne and Wear, United Kingdom
    Neurology 62:S32-6. 2004
    ....
  49. ncbi Effects of acute and chronic apomorphine on sex behavior and copulation-induced neural activation in the male rat
    Jocelien D A Olivier
    Department of Anatomy, UMC St Radboud, University of Nijmegen, The Netherlands
    Eur J Pharmacol 576:61-76. 2007
    ....
  50. pmc The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence
    Christian A Heidbreder
    Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy
    Brain Res Brain Res Rev 49:77-105. 2005
    ..Provided these results can be extrapolated to human drug addicts, they suggest that selective DA D3 receptor antagonists may prove effective as potential pharmacotherapeutic agents to manage drug dependence and addiction...
  51. doi Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor
    Nuska Tschammer
    Department of Chemistry and Pharmacy, Friedrich Alexander University, Erlangen, Germany
    Mol Pharmacol 79:575-85. 2011
    ..Overall, the residue His393(6.55) and proximate molecular substructures of receptor ligands were identified to be crucial for multidimensional ligand efficacy...
  52. pmc The time course of dopamine transmission in the ventral tegmental area
    Christopher P Ford
    Vollum Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Neurosci 29:13344-52. 2009
    ..Thus, dopamine transmission in the midbrain is more localized then previously proposed...
  53. ncbi Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome
    Sergio Reis Soares
    Instituto Valenciano de Infertilidad, IVI Lisboa Av Infante Dom Henrique, 333 H, 1800 282 Lisbon, Portugal
    Hum Reprod Update 14:321-33. 2008
    ..Ovarian hyperstimulation syndrome (OHSS) typically occurs when ovaries are primed with FSH/LH and subsequently exposed to hCG. The ultimate pathophysiological step underlying this clinical picture is increased vascular permeability (VP)...
  54. doi Efficacy and safety of dopamine agonists in traumatic brain injury: a systematic review of randomized controlled trials
    Anne Julie Frenette
    Department of Pharmacy, Hopital du Sacre Coeur de Montreal, Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada
    J Neurotrauma 29:1-18. 2012
    In the intensive care unit, dopamine agonists (DA) have been used in traumatic brain injury (TBI) patients to augment or accelerate cognitive recovery and rehabilitation...
  55. ncbi Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes
    Richard Scranton
    Veroscience LLC, 1334 Main Road, Tiverton, RI 02878, USA
    Expert Opin Pharmacother 11:269-79. 2010
    ..The quick-release formulation of bromocriptine (bromocriptine-QR; Cycloset) represents such a therapy...
  56. ncbi Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor
    Sarah L Payne
    School of Animal and Microbial Sciences, University of Reading, UK
    J Neurochem 82:1106-17. 2002
    ....
  57. ncbi Physiology and pathology of ovarian hyperstimulation syndrome
    Raul Gomez
    Instituto Universitario IVI, Universidad de Valencia, Valencia, Spain
    Semin Reprod Med 28:448-57. 2010
    ..Pharmaco-prevention through dopamine agonists is effective only in nonpregnant high-risk OHSS women...
  58. ncbi Clinical practice. Prolactinoma
    Janet A Schlechte
    Department of Internal Medicine, University of Iowa, Iowa City, USA
    N Engl J Med 349:2035-41. 2003
  59. ncbi Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
    Lisa M Neff
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts New England Medical Center, Boston, MA 02111, USA
    Pituitary 10:81-6. 2007
    Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients ..
  60. ncbi Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo
    Rajesh Narendran
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York 10032, USA
    Synapse 60:485-95. 2006
    ..This property might contribute to its higher vulnerability to endogenous DA compared to [11C]raclopride and [11C]NPA...
  61. ncbi The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells
    J E de Leeuw van Weenen
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Biochem Pharmacol 79:1827-36. 2010
    ..We suggest that treatment with bromocriptine promotes beta cells rest, thereby preventing long-lasting hypersecretion of insulin and subsequent beta cell failure...
  62. pmc Ovarian hyperstimulation syndrome: pathophysiology and prevention
    Carolina O Nastri
    Departamento de Ginecologia e Obstetrícia da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo DGO HC FMRP USP, Avenida dos Bandeirantes 3900, 8 masculine Andar, Ribeirao Preto, Sao Paulo, Brazil, CEP 14049 900
    J Assist Reprod Genet 27:121-8. 2010
    ..To review and discuss the pathophysiology and prevention strategies for ovarian hyperstimulation syndrome (OHSS), which is a condition that may occur in up to 20% of the high risk women submitted to assisted reproductive technology cycles...
  63. ncbi Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment
    Raul Gomez
    Fundacion IVI, Institituto Universitario IVI Fundación Investigación Clinico de Valencia INCLIVA, 46015 Valencia, Spain
    J Clin Endocrinol Metab 96:2484-92. 2011
    ..Deregulation of the VEGF/VEGF receptor (VEGFR)-2 pathway leading to increased risk of ovarian hyperstimulation syndrome has been described in the ovary of patients suffering from polycystic ovarian syndrome (PCOS)...
  64. ncbi Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table
    Katherine Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 19:1370-4. 2004
    Of 99 patients on ergot-derived dopamine agonists informed about possible long-term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%...
  65. ncbi Neural cell adhesion molecule modulates dopaminergic signaling and behavior by regulating dopamine D2 receptor internalization
    Mei fang Xiao
    Zentrum für Molekulare Neurobiologie, Universitatsklinikum Hamburg Eppendorf, D 20246 Hamburg, Germany
    J Neurosci 29:14752-63. 2009
    ....
  66. doi Efficacy and safety of dopamine agonists in restless legs syndrome
    Magdolna Hornyak
    Interdisciplinary Pain Centre, University Medical Centre, Breisacher Strasse 64, 79106 Freiburg, Germany
    Sleep Med 13:228-36. 2012
    ..This article is an overview of a comprehensive Cochrane meta-analysis on the efficacy and safety of dopamine agonists (DAs), the first-line treatment of RLS.
  67. doi Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
    Sophie Vallette
    Department of Endocrinology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Sherbrooke East, Montreal, QC, H2L 4M1, Canada
    Expert Rev Cardiovasc Ther 8:49-54. 2010
    b>Dopamine agonists (DAs) are the first-line therapy for the treatment of hyperprolactinemia, with cabergoline, an ergot-derived selective D(2)-receptor agonist, being the preferred and most widely used drug...
  68. doi Cognitive status of patients with Parkinson's disease and pathological gambling
    Chiara Siri
    Parkinson Institute, Istituti Clinici di Perfezionamento, 20126, Milan, Italy
    J Neurol 257:247-52. 2010
    ..In conclusion the occurrence of PG in our cohort of patients with PD was associated with preserved executive functions...
  69. doi Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia
    Andrew J Holman
    Pacific Rheumatology Research, 4300 Talbot Road South, Suite 101, Renton, WA, 98055, USA
    J Gambl Stud 25:425-31. 2009
    Compulsivity has been associated with use of dopamine agonists used to treat Parkinson's disease (PD). Increasing use of these agents to treat fibromyalgia (FM) raises concern for this unexpected toxicity in a new group of patients...
  70. ncbi Pregnancy outcome after cabergoline treatment in early weeks of gestation
    Elena Ricci
    Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62 20157, Milan, Italy
    Reprod Toxicol 16:791-3. 2002
    ..The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline...
  71. ncbi Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series
    David A Gallagher
    Department of Clinical Neurosciences, Royal Free and University College Medical School, London, United Kingdom
    Mov Disord 22:1757-63. 2007
    ..cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS)...
  72. pmc Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence
    Karen D Ersche
    University of Cambridge, Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, Cambridge, England
    Arch Gen Psychiatry 67:632-44. 2010
    ..We hypothesized that dopamine-related targets are relevant for treatment of stimulant dependence, and there will likely be individual differences in response to dopaminergic challenges...
  73. ncbi Dopamine agonists and sleepiness in PD: review of the literature and personal findings
    Raffaele Manni
    Unit of Sleep Medicine and Epilepsy, IRCCS C Mondino Institute of Neurology, Pavia, Italy
    Sleep Med 5:189-93. 2004
    This study is aimed at evaluating daytime sleepiness in a series of Parkinson's disease (PD) patients chronically treated with dopamine agonists (DAs) alone or in combination with L-Dopa.
  74. ncbi Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia
    Mark Stacy
    Division of Neurology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Neuropharmacol 31:51-6. 2008
    The treatment of Parkinson disease (PD) involves pharmacological treatment, often with levodopa or dopamine agonists, to restore the dopaminergic deficit associated with parkinsonian symptoms...
  75. ncbi Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers
    M A Mehta
    Department of Psychiatry, University of Cambridge, School of Clinical Medicine, Addenbrooke s Hospital, UK
    Psychopharmacology (Berl) 159:10-20. 2001
    ..Studies in humans of cognitive effects of dopaminergic drugs have largely focused on tasks of working memory, with a few studies also examining executive function...
  76. ncbi Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up
    A Colao
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II di Napoli, Naples, Italy
    J Clin Endocrinol Metab 83:2777-80. 1998
    ..In conclusion, the medical treatment with dopaminergic compounds is effective and safe in patients with prolactinoma with onset in childhood, allowing preservation of the anterior pituitary function...
  77. pmc Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
    Thilo van Eimeren
    Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada
    Neuropsychopharmacology 34:2758-66. 2009
    ..Treatment with dopamine agonists (DAs) has been associated with pathological gambling in PD patients...
  78. ncbi Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women
    Petra Kok
    Department of Internal Medicine C4 83, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    J Clin Endocrinol Metab 91:3236-40. 2006
    ..This study was done to establish the effect of bromocriptine treatment on circadian plasma leptin concentrations in obese humans...
  79. ncbi A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory
    Sasha E B Gibbs
    Henry H Wheeler Jr Brain Imaging Center, Helen Wills Neuroscience Institute and Department of Psychology, University of California, Berkeley, 132 Barker Hall, Berkeley, CA 94720 3190, USA
    Psychopharmacology (Berl) 180:644-53. 2005
    ....
  80. ncbi Chemistry of the adaptive mind
    Roshan Cools
    Department of Experimental Psychology, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK
    Philos Trans A Math Phys Eng Sci 362:2871-88. 2004
    ..The work has considerable implications for the understanding of and treatment development for abnormalities such as Parkinson's disease, attention deficit hyperactivity disorder and drug addiction...
  81. ncbi Prevalence of repetitive and reward-seeking behaviors in Parkinson disease
    V Voon
    Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1428, USA
    Neurology 67:1254-7. 2006
    ..4%. Compulsive shopping was 0.7%. Combined with our pathologic gambling data, the lifetime prevalence of these behaviors was 6.1% and increases to 13.7% in patients on dopamine agonists.
  82. ncbi Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies
    F Bogazzi
    Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
    J Endocrinol Invest 31:1119-23. 2008
    b>Dopamine agonists have been associated with increased risk of cardiac valve regurgitation in patients with Parkinson's disease. Whether these drugs might be harmful for patients with hyperprolactinemia is still unsettled...
  83. ncbi Cabergoline and the risk of valvular lesions in endocrine disease
    Patrizio Lancellotti
    Department of Cardiology, Centre Hospitalier Universitaire de Liege, Domaine Universitaire du Sart Tilman, University of Liege, B 4000 Liege, Belgium
    Eur J Endocrinol 159:1-5. 2008
    ..The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown...
  84. doi Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease
    Ammar Wakil
    Michael White Diabetes Centre, Hull Royal Infirmary, Brocklehurst Building, 220 236 Anlaby Road, Hull HU3 2RW, UK
    Eur J Endocrinol 159:R11-4. 2008
    Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease...
  85. ncbi Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice
    Rebecca J Ralph-Williams
    Alcohol and Drug Abuse Research Center, Harvard Medical School and McLean Hospital, Belmont, Massachusetts 02478, USA
    J Neurosci 22:9604-11. 2002
    ..These findings emphasize that further cross-species comparisons of the pharmacology of PPI are essential to understand the relevance of rodent PPI studies to the deficits in PPI observed in patients with schizophrenia...
  86. ncbi Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging
    Marina Delfino
    Laboratorio de Parkinsonismo Experimental, Instituto de Investigaciones Farmacologicas, CONICET, Buenos Aires, Argentina
    Neuropsychopharmacology 32:1911-21. 2007
    ..As a first step towards disclosing drug-induced brain activation in dyskinesia, we examined the effects of dopamine agonists on behavior and blood oxygenation level-dependent (BOLD) signal in the striatum and motor cortex of rats ..
  87. ncbi Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
    Alan L Whone
    Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 54:93-101. 2003
    ..1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by (18)F-dopa PET...
  88. ncbi Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series
    G Perugi
    Department of Psychiatry, University of Pisa, Italy
    Pharmacopsychiatry 34:137-41. 2001
    Previous studies and case observations have suggested that dopamine agonists (DAAs) such as pramipexole (PPX) and ropinirole (RPN) might be effective for major depression, but their adjunctive use in treatment-resistant bipolar II ..
  89. ncbi Compulsive eating and weight gain related to dopamine agonist use
    Melissa J Nirenberg
    Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, NY 10021, USA
    Mov Disord 21:524-9. 2006
    b>Dopamine agonists have been implicated in causing compulsive behaviors in patients with Parkinson's disease (PD). These have included gambling, hypersexuality, hobbyism, and other repetitive, purposeless behaviors ("punding")...
  90. ncbi Clinical features associated with impulse control disorders in Parkinson disease
    Gregory Pontone
    Department of Psychiatry and Behavioral Sciences, Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Neurology 67:1258-61. 2006
    ..Subjects were participants in a longitudinal study of PD. ICDs were associated with use of dopamine agonists and depressed mood, disinhibition, irritability, and appetite disturbance.
  91. ncbi Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas
    M Biswas
    Department of Endocrinology, University Hospital of Wales, Heath Park, Cardiff, Wales, UK
    Clin Endocrinol (Oxf) 63:26-31. 2005
    ..Subjects received dopamine agonist (DA) therapy with either cabergoline or bromocriptine for a period of 2 to 3 years in the majority of cases, followed by a trial of treatment withdrawal...
  92. ncbi Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy
    A Di Sarno
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, 80131 Naples, Italy
    J Clin Endocrinol Metab 86:5256-61. 2001
    ..Therefore, an absence of tumor shrinkage cannot be considered as end point to indicate resistance to CAB, and increasing the dose of CAB higher than 3 mg/wk does not seem to be helpful in controlling PRL hypersecretion...
  93. doi Prevalence of problem and pathological gambling in Parkinson's disease
    David Crockford
    Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada, T2N 2T9
    J Gambl Stud 24:411-22. 2008
    Pathological gambling (PG) has been identified in patients with Parkinson's disease (PD) treated with dopamine agonists suggesting that dysregulation of brain dopaminergic activity may contribute to the development of gambling problems...
  94. doi Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required
    M Kars
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Endocrinol 159:363-7. 2008
    ..Parkinson's disease with cabergoline has raised concerns about the safety of treatment with ergot-derived dopamine agonists in patients with endocrine diseases, especially prolactinoma...
  95. ncbi Prolactinomas and pregnancy
    Marcello Delano Bronstein
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of S Paulo Medical School, Av 9 de Julho 3858, 01406 100, S Paulo, SP, Brazil
    Pituitary 8:31-8. 2005
    ..Since then, dopamine agonists (DA) have been increasingly used as the first-choice treatment of prolactinomas, with surgery being reserved ..
  96. ncbi Dopamine agonist withdrawal syndrome in Parkinson disease
    Christina A Rabinak
    Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York 10021, USA
    Arch Neurol 67:58-63. 2010
    ..To report and characterize a dopamine agonist (DA) withdrawal syndrome (DAWS) in Parkinson disease...
  97. ncbi Rotigotine transdermal delivery for the treatment of Parkinson's disease
    Olivier Rascol
    Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse, France
    Expert Opin Pharmacother 10:677-91. 2009
    ..An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications...
  98. ncbi Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists
    Vanessa Q Passos
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil
    Neuroendocrinology 89:163-70. 2009
    ..Prolactinomas are the most common secreting pituitary adenomas, and dopamine agonists (DA) are the first choice for their treatment. However, a subset of patients is resistant to DA...
  99. doi Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance
    Isabel Garcia-Tornadú
    Instituto de Biologia y Medicina Experimental CONICET, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina
    Endocrinology 151:1441-50. 2010
    ..Pancreatic D2Rs inhibit glucose-stimulated insulin release. Lack of dopaminergic inhibition throughout development may exert a gradual deteriorating effect on insulin homeostasis, so that eventually glucose intolerance develops...
  100. ncbi Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias
    M A Delfino
    Laboratorio de Parkinson Experimental, ININFA CONICET, Junin 956, 5 degrees piso, C1113AAD Buenos Aires, Argentina
    Behav Brain Res 152:297-306. 2004
    ....
  101. pmc Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists
    Karina L Bienfait
    Department of Psychiatry, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ 08854, USA
    J Clin Neurosci 17:539-40. 2010
    ..We postulate this to be related to an overstimulation of mesolimbic dopamine receptors responsible for reward-seeking behaviors. Further research is needed to examine impulsive cigarette smoking in PD...

Research Grants80

  1. CATECHOLAMINES AND SEROTONIN IN BLOOD PRESSURE CONTROL
    Curt Freed; Fiscal Year: 1990
    ..Serotonin agonists, alpha-2 receptor agonists and dopamine agonists have all been shown to lower blood in hypertensive animals...
  2. AUTORECEPTOR REGULATION OF DOPAMINE RELEASE
    JOSEPH MASSERANO; Fiscal Year: 1990
    ..of dopamine release in these five brain regions by performing dose response curves with the D2 selective dopamine agonists, pergolide and quinpirole; the D1 selective dopamine agonist SKF 38393; the non- selective dopamine ..
  3. COCAINE INDUCED OPIOID, DOPAMINE AND BEHAVIORAL CHANGES
    ELLEN UNTERWALD; Fiscal Year: 2001
    ..The potential outcome of these studies may be the information necessary for the development of more selective pharmacotherapeutic agents for the chronic management of cocaine addiction. ..
  4. COCAINE INDUCED OPIOID, DOPAMINE AND BEHAVIORAL CHANGES
    ELLEN UNTERWALD; Fiscal Year: 2002
    ..The potential outcome of these studies may be the information necessary for the development of more selective pharmacotherapeutic agents for the chronic management of cocaine addiction. ..
  5. COCAINE INDUCED OPIOID, DOPAMINE AND BEHAVIORAL CHANGES
    ELLEN UNTERWALD; Fiscal Year: 1999
    ..The potential outcome of these studies may be the information necessary for the development of more selective pharmacotherapeutic agents for the chronic management of cocaine addiction. ..
  6. COCAINE INDUCED OPIOID, DOPAMINE AND BEHAVIORAL CHANGES
    ELLEN UNTERWALD; Fiscal Year: 2000
    ..The potential outcome of these studies may be the information necessary for the development of more selective pharmacotherapeutic agents for the chronic management of cocaine addiction. ..
  7. Extrastriatal functions of dopamine
    THOMAS N WICHMANN; Fiscal Year: 2010
    ..If significant dopaminergic effects are seen in the subthalamic nucleus, it may emerge as a new target for highly specific local dopamine replacement therapies for parkinsonian patients. ..
  8. SEN 3614:RANDOM ,DBL BLIND,PLACEBO CONT STUDY OF B2036 PEG IN TREAT A
    Pamela Freda; Fiscal Year: 2000
    ..All patients have growth hormone receptors so we expect that this drug should have an effect in nearly all patients unlike the medications which are currently available which are effective in only 20-60% of subjects ..
  9. Enzymatic Regulation of S-Glutathionylation : Role in Apoptosis and Disease
    John J Mieyal; Fiscal Year: 2011
    ..Increased knowledge of how these enzymes regulate the balance between cell survival and cell death will promote innovative therapeutic development. ..
  10. ULTRASTRUCTURE OF MESOLIMBIC TRANSMITTER INTERACTIONS
    Virginia M Pickel; Fiscal Year: 2010
    ....
  11. ULTRASTRUCTURE OF MESOLIMBIC TRANSMITTER INTERACTIONS
    VIRGINIA PICKEL; Fiscal Year: 2009
    ....
  12. Subtype Specific Agonists for D1-D5 Dopamine Receptors
    William Goddard; Fiscal Year: 2007
    ..receptors can induce side effects similar to those resulting from dopamine depletion, and high doses of dopamine agonists can cause psychoses...
  13. Subtype Specific Agonists for D1-D5 Dopamine Receptors
    William Goddard; Fiscal Year: 2006
    ..receptors can induce side effects similar to those resulting from dopamine depletion, and high doses of dopamine agonists can cause psychoses...
  14. LONG TERM EFFECTS OF STIMULANT MEDICATIONS POSSIBLE RELEVANCE TO ADHD TREATMENT
    Martin Goulet; Fiscal Year: 2000
    ..therapy include direct agonists that activate the targets of dopamine, D1 and D2 dopamine receptors Several dopamine agonists have been tried as monotherapies at the onset of therapy (Hoehn and Yahr stage I-III), as substitutes for L-..
  15. MOTOR FUNCTIONS OF THE BASAL GANGLIA
    Mahlon Delong; Fiscal Year: 1992
    ....
  16. Long-term non-fluctuating dopamine agonist delivery for Parkinson's disease
    SUNIL P contact SREEDHARAN; Fiscal Year: 2010
    ..The cornerstone of symptomatic treatment for PD is dopamine replacement therapy, and dopamine agonists (DA) are used as monotherapy to improve symptoms in early disease or as adjuncts to levodopa (LD) in ..
  17. Role of Endocannabinoids in Levodopa-Induced Dyskinesias
    Andrea Giuffrida; Fiscal Year: 2006
    ..In conclusion, our study will elucidate the role of the endocannabinoid system in levodopa-associated dyskinesias and provide a rational to develop new treatments that act via the endocannabinoid system. ..
  18. Role of Endocannabinoids in Levodopa-Induced Dyskinesias
    Andrea Giuffrida; Fiscal Year: 2007
    ..In conclusion, our study will elucidate the role of the endocannabinoid system in levodopa-associated dyskinesias and provide a rational to develop new treatments that act via the endocannabinoid system. ..
  19. Role of Endocannabinoids in Levodopa-Induced Dyskinesias
    Andrea Giuffrida; Fiscal Year: 2005
    ..In conclusion, our study will elucidate the role of the endocannabinoid system in levodopa-associated dyskinesias and provide a rational to develop new treatments that act via the endocannabinoid system. ..
  20. DEVELOPMENT OF POTENTIALLY SELECTIVE DOPAMINE AGONISTS
    David Nichols; Fiscal Year: 1999
    ....
  21. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2005
    ..to challenges with dopaminergic agents in later life such that animals are more sensitive to the effects of dopamine agonists and less sensitive to those of dopamine antagonists...
  22. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2006
    ..to challenges with dopaminergic agents in later life such that animals are more sensitive to the effects of dopamine agonists and less sensitive to those of dopamine antagonists...
  23. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2003
    ..to challenges with dopaminergic agents in later life such that animals are more sensitive to the effects of dopamine agonists and less sensitive to those of dopamine antagonists...
  24. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2007
    ..to challenges with dopaminergic agents in later life such that animals are more sensitive to the effects of dopamine agonists and less sensitive to those of dopamine antagonists...
  25. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2004
    ..to challenges with dopaminergic agents in later life such that animals are more sensitive to the effects of dopamine agonists and less sensitive to those of dopamine antagonists...
  26. DEVELOPMENT OF POTENTIALLY SELECTIVE DOPAMINE AGONISTS
    David Nichols; Fiscal Year: 2000
    ....
  27. MECHANISMS GOVERNING ONSET OF OVARIAN FUNCTION
    Kathleen Ryan; Fiscal Year: 1990
    ..Thus an added tool is available to allow the distinction of somatic changes from pubertal changes, and the separation of photoperiod specific changes from puberty specific ones - a truly exciting prospect...
  28. Medications for Comorbid Cocaine and Alcohol Dependence
    Rolley Johnson; Fiscal Year: 2002
    ..Over the past decade, medications including dopamine agonists, antagonists, tricyclic antidepressants, selective serotonin reuptake inhibitors, opiate mixed agonist-..
  29. Dopamine and the Role of Anterior Cingulate Cortex in Executive Processes
    Benjamin Y Hayden; Fiscal Year: 2010
    ..The goal of this project is to characterize the role of dopamine in governing executive functions, including resisting temptation and adjusting behavior following poor choices. ..
  30. D1 AGONISTS ARE MORE EFFECTIVE IN ADVANCED THAN IN MILD PARKINSONISM
    Martin Goulet; Fiscal Year: 2000
    ..focuses mainly on dopamine replacement with L-Dopa, which requires conversion to dopamine in the brain, or dopamine agonists, which directly stimulate dopamine receptors Of the two families of dopamine receptors, D1-like ( D1, D5) ..
  31. TREATMENT RESEARCH UNIT--REDUCING AIDS RISKS
    Thomas Kosten; Fiscal Year: 1991
    ..Project 1 will examine dopamine agonists (amantadine, bromocriptine, mazindol) and antagonists (flupenthixol) and serotonergic augmentation of ..
  32. BASAL GANGLIA DISORDERS AND NEUROTRANSMITTER FUNCTION
    NORMAN WEINER; Fiscal Year: 1990
    ..Autoreceptors are believed to be important in actions and side effects of dopamine agonists and antagonists used in the treatment of Parkinson's disease and schizophrenia...
  33. The neurogenic potential of cholinergic activation in AD.
    ELIZABETH ADAMS ECKMAN; Fiscal Year: 2010
    ..If successful, these studies may yield novel insights into potential treatment strategies and will also increase our understanding of the factors capable of regulating new cell formation in the adult brain. ..
  34. The neurogenic potential of cholinergic activation in AD.
    Elizabeth Eckman; Fiscal Year: 2009
    ..If successful, these studies may yield novel insights into potential treatment strategies and will also increase our understanding of the factors capable of regulating new cell formation in the adult brain. ..
  35. BRAIN DOPAMINE REGULATION OF MALE SEX BEHAVIOR IN RATS
    Elaine Hull; Fiscal Year: 1990
    ....
  36. NEUROPHARMACOLOGY OF ETHANOL REINFORCEMENT
    George Koob; Fiscal Year: 1990
    ..shown that low doses of ethanol can release dopamine in the region of the nucleus accumbens and that dopamine agonists appear to reduce ethanol preference without decreasing water intake...
  37. NEUROPHARMACOLOGY OF ETHANOL REINFORCEMENT
    George Koob; Fiscal Year: 1991
    ..shown that low doses of ethanol can release dopamine in the region of the nucleus accumbens and that dopamine agonists appear to reduce ethanol preference without decreasing water intake...
  38. PHARMACOLOGICAL SUBSTRATES OF AMPHETAMINE ADDICTION
    Lisa Brauer; Fiscal Year: 2000
    ..abstract_text> ..
  39. PHARMACOLOGICAL SUBSTRATES OF AMPHETAMINE ADDICTION
    Lisa Brauer; Fiscal Year: 2001
    ..abstract_text> ..
  40. PHARMACOLOGICAL SUBSTRATES OF AMPHETAMINE ADDICTION
    Lisa Brauer; Fiscal Year: 1999
    ..abstract_text> ..
  41. Regulation and function of Nurr1 in adult nigrostriatal dopamine neurons
    JEFFREY EELLS; Fiscal Year: 2009
    ....
  42. DEVELOPMENT OF POTENTIALLY SELECTIVE DOPAMINE AGONISTS
    David Nichols; Fiscal Year: 2006
    ..Our work will generate molecular probes that should help to increase our understanding of these pathways, and may also provide new therapies for disorders such as Parkinson's disease and schizophrenia. ..
  43. DEVELOPMENT OF POTENTIALLY SELECTIVE DOPAMINE AGONISTS
    David Nichols; Fiscal Year: 2009
    ..Our work will generate molecular probes that should help to increase our understanding of these pathways, and may also provide new therapies for disorders such as Parkinson's disease and schizophrenia. ..
  44. DEVELOPMENT OF POTENTIALLY SELECTIVE DOPAMINE AGONISTS
    David Nichols; Fiscal Year: 2007
    ..Our work will generate molecular probes that should help to increase our understanding of these pathways, and may also provide new therapies for disorders such as Parkinson's disease and schizophrenia. ..
  45. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. [unreadable] [unreadable] [unreadable] [unreadable]..
  46. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. [unreadable] [unreadable] [unreadable] [unreadable]..
  47. A Genetic Test for Drug-Induced Dyskinesia Risk
    Abraham Kovoor; Fiscal Year: 2006
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. [unreadable] [unreadable] [unreadable] [unreadable]..
  48. STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICE
    Mark Geyer; Fiscal Year: 2002
    ..habituation, and prepulse inhibition; (3) characterize the effects of amphetamine and selected direct dopamine agonists on the same measures; (4) characterize the effects of amphetamine and selected direct dopamine agonists on ..
  49. STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICE
    Mark Geyer; Fiscal Year: 2000
    ..habituation, and prepulse inhibition; (3) characterize the effects of amphetamine and selected direct dopamine agonists on the same measures; (4) characterize the effects of amphetamine and selected direct dopamine agonists on ..
  50. STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICE
    Mark Geyer; Fiscal Year: 2003
    ..habituation, and prepulse inhibition; (3) characterize the effects of amphetamine and selected direct dopamine agonists on the same measures; (4) characterize the effects of amphetamine and selected direct dopamine agonists on ..
  51. STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICE
    Mark Geyer; Fiscal Year: 2004
    ..habituation, and prepulse inhibition; (3) characterize the effects of amphetamine and selected direct dopamine agonists on the same measures; (4) characterize the effects of amphetamine and selected direct dopamine agonists on ..
  52. STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICE
    Mark Geyer; Fiscal Year: 2001
    ..habituation, and prepulse inhibition; (3) characterize the effects of amphetamine and selected direct dopamine agonists on the same measures; (4) characterize the effects of amphetamine and selected direct dopamine agonists on ..
  53. NON-NITROGEN AND NITROGEN CONTAINING DOPAMINE DRUGS
    Duane Miller; Fiscal Year: 1990
    ..4.To synthesize a set of formamidino, guanidino and thiourea analogs of DA, in order to investigate the overall importance of hydrogen bonding in the interaction of DAergic drugs with DAergic receptors...
  54. ON-OFF MOOD CHANGE IN PARKINSONS DISEASE
    Kevin Black; Fiscal Year: 1999
    ..The localized effects of specific dopamine agonists on cerebral blood flow (rCBF) measured with PET will be used to indicate changes in neuronal activity...
  55. ON-OFF MOOD CHANGE IN PARKINSONS DISEASE
    Kevin Black; Fiscal Year: 2000
    ..The localized effects of specific dopamine agonists on cerebral blood flow (rCBF) measured with PET will be used to indicate changes in neuronal activity...
  56. Parkinson's Disease Neuroprotection Clinical Center
    Charles Adler; Fiscal Year: 2003
    ..levodopa, dopamine agonists)...
  57. SCIENTIST DEVELOPMENT AWARD FOR A CLINICIAN
    Kyle Kampman; Fiscal Year: 1999
    ....
  58. Parkinson's Disease Neuroprotection Clinical Center
    Charles Adler; Fiscal Year: 2002
    ..levodopa, dopamine agonists)...
  59. BASAL GANGLIA GABA-DOPAMINE INTERACTIONS
    James Bennett; Fiscal Year: 1990
    ....
  60. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben Jonathan; Fiscal Year: 2010
    ..Aim 4: To establish mixed-cultures of fully differentiated LS14 adipocytes and BCC and examine whether dopamine agonists sensitize LS14/BCC tumors in athymic mice to anticancer drugs...
  61. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben Jonathan; Fiscal Year: 2009
    ..Aim 4: To establish mixed-cultures of fully differentiated LS14 adipocytes and BCC and examine whether dopamine agonists sensitize LS14/BCC tumors in athymic mice to anticancer drugs...
  62. New Dopamine D1 Agonists as PET Imaging Agents
    ONOFRE DEJESUS; Fiscal Year: 2007
    ..Because the high Affinity state is the physiologically functional state, dopamine agonists are preferred as PET imaging agents since they can discriminate between high and low affinity states...
  63. X RAY MAPPING OF DOPAMINE D2 AGONISTS
    CHERYL KLEIN; Fiscal Year: 2000
    This study is designed to "map" the three dimensional structure and electronic character of a series of dopamine agonists. The specific agonists will be chosen from classes of compounds that are known to have dopaminergic activity...
  64. X RAY MAPPING OF DOPAMINE D2 AGONISTS
    CHERYL KLEIN; Fiscal Year: 2001
    This study is designed to "map" the three dimensional structure and electronic character of a series of dopamine agonists. The specific agonists will be chosen from classes of compounds that are known to have dopaminergic activity...
  65. SELF-INJURIOUS BEHAVIOR: MOLECULAR MARKERS
    DARRAGH DEVINE; Fiscal Year: 2001
    ....
  66. SELF-INJURIOUS BEHAVIOR: MOLECULAR MARKERS
    DARRAGH DEVINE; Fiscal Year: 2002
    ....
  67. PARTIAL DOPAMINE AGONIST TREATMENT OF SCHIZOPHRENIA
    Carol Tamminga; Fiscal Year: 2000
    ..These data will predict and later help us to select optimal agonist intrinsic activity ior clinical testing for antipsychotic actvity, duration of therapeutic action, and side effects. ..
  68. PRO LEU GLY NH2 AMD DOPAMINE RECEPTOR MODULATION STUDY
    Rodney Johnson; Fiscal Year: 1999
    ..1) the ability of Gs and Gi antisense oligonucleotides to modulate rotational behavior induced by dopamine agonists in 6-hydroxydopamine lesioned rats in the presence and absence of PLG analogues; (2) the G protein levels ..
  69. Excitatory and Inhibitory Pathways for Cocaine Treatment
    Edward Nunes; Fiscal Year: 1999
    ..and addictive properties of cocaine remains clear, but the lack of success with anti-depressants and dopamine agonists in clinical trials suggests other approaches to manipulating the dopamine system in cocaine dependent ..
  70. Cocaine effects on neurons
    John T Williams; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Dopamine agonists and antagonists are used clinically for the treatment of a number of diseases pointing out the importance of ..
  71. Excitatory and Inhibitory Pathways for Cocaine Treatment
    Edward Nunes; Fiscal Year: 2002
    ..and addictive properties of cocaine remains clear, but the lack of success with anti-depressants and dopamine agonists in clinical trials suggests other approaches to manipulating the dopamine system in cocaine dependent ..
  72. Excitatory and Inhibitory Pathways for Cocaine Treatment
    Edward Nunes; Fiscal Year: 2000
    ..and addictive properties of cocaine remains clear, but the lack of success with anti-depressants and dopamine agonists in clinical trials suggests other approaches to manipulating the dopamine system in cocaine dependent ..
  73. Excitatory and Inhibitory Pathways for Cocaine Treatment
    Edward Nunes; Fiscal Year: 2001
    ..and addictive properties of cocaine remains clear, but the lack of success with anti-depressants and dopamine agonists in clinical trials suggests other approaches to manipulating the dopamine system in cocaine dependent ..